Responder analyses and the assessment of a clinically relevant treatment effect
2007

Analyzing Clinical Relevance in Trials

publication Evidence: moderate

Author Information

Author(s): Steven M Snapinn, Qi Jiang

Primary Institution: Amgen Inc.

Hypothesis

Can the responder analysis effectively demonstrate clinically relevant treatment effects in clinical trials?

Conclusion

The responder analysis is less efficient than analyzing the original continuous variable and does not reliably determine clinical relevance.

Supporting Evidence

  • The responder analysis often requires a larger sample size compared to traditional methods.
  • Statistical significance does not guarantee clinical relevance.
  • Arbitrary thresholds in responder analysis can lead to misleading conclusions about treatment efficacy.

Takeaway

This study looks at how we measure if a treatment really helps people, and it finds that a common method might not be the best way to do it.

Methodology

The paper discusses the responder analysis method and its weaknesses in assessing clinical relevance compared to continuous variable analysis.

Potential Biases

The responder analysis may misinterpret treatment effects due to its reliance on arbitrary thresholds.

Limitations

The responder analysis can lead to arbitrary definitions of response and may not accurately reflect clinical significance.

Digital Object Identifier (DOI)

10.1186/1745-6215-8-31

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication